Martin Gebel

机构：Bayer (Germany) · ORCID：0000-0003-0812-8490

发表论文 57 篇 · 总被引 3109 次 · h-index 19

代表论文

• Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2021 · European Heart Journal · 被引 1239)
• Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis (2022 · Diabetes Care · 被引 207)
• Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism (2021 · Annals of Internal Medicine · 被引 141)
• Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone (2020 · Nephrology Dialysis Transplantation · 被引 114)
• A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease (2022 · Clinical Kidney Journal · 被引 103)
• Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis (2021 · Journal of Thrombosis and Haemostasis · 被引 51)